Yaron Daniely

Lyfegen is an independent provider of access, pricing and rebate management software designed for the healthcare industry. Lyfegen solutions are used by health insurances, governments, hospital payers, and pharmaceutical companies around the globe to dramatically reduce the administrative burden of implementing and managing complex drug pricing agreements and to optimize rebates and get better value from those agreements. Lyfegen maintains the world’s largest digital repository of innovative drug pricing models and public agreements and offers access to a robust drug pricing simulator designed to dynamically simulate complex drug pricing scenarios to understand full financial impact. Headquartered in Basel, Switzerland, the company was founded in 2018 and has a market presence in Europe, North America, and the Middle East.

Cavos Biotech is an emerging genomic and data science company focusing on the development of novel drugs based on naturally occurring resistance mechanisms for various diseases. We are developing a multi-level genomic algorithm to uncover the genetic base of extraordinary cancer resistance found in specific, and across various animals. We harness the genomic and data revolution and use high resolution identification methods to uncover existing anti-cancer mechanisms, and novel drug targets, and to revolutionize the way by which drug targets are discovered and identified.

MetaSight Diagnostics, a health technology company, is on a mission to create affordable and precise liquid biopsy diagnostics for early detection of a variety of chronic and acute diseases, utilizing proprietary, cost-effective mass spectrometry technologies (metabolomics, lipidomics and proteomics). The company has created the world’s largest and most comprehensive serum metabolomics dataset linked with Electronic Health Records and is pursuing additional omics. This unprecedented platform is used by MetaSight’s team of experts in analytical chemistry, AI, and medicine to develop and commercialize diagnostic products to improve human health.

Lin Health partners with payers and providers to help people reclaim their lives from chronic pain through human-led, tech-enabled, highly personalized care. Our award-winning, comprehensive approach applies the latest neuroscience to treat conditions as diverse as migraines, IBS, and back and joint pain. We partner with health systems, clinics, and payers as an integrated extension of the care team to offer patients an affordable, immediately accessible, and non-pharmacological solution for highly prevalent neuroplastic pain. Our clinically validated intervention targets the nervous system by combining the most effective pain signaling techniques, incorporating multidisciplinary clinical guidance, high-frequency coaching, evidence-based digital resources, and proprietary technology to improve patient outcomes, patient and provider satisfaction, and clinic success. Our proprietary AI-based Care Platform provides rapid scalability and has served thousands of patients in the past 12-months. Lin Health was founded by industry veterans and is funded by leading investors.

Nectin Therapeutics is a biotech company focused on unlocking the power of the immune system. We are developing a collection of next-generation immunotherapy agents. Despite the unprecedented efficacy of existing immunotherapy agents, many patients either fail to respond, or following encouraging initial response, develop resistance over time. At Nectin, we have discovered novel resistance mechanisms and developed novel agents targeting these mechanisms for improved therapy. At Nectin, we are dedicated to the development of novel therapeutic options for cancer patients. We are developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, we develop CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers.

Lyfegen is an independent provider of access, pricing and rebate management software designed for the healthcare industry. Lyfegen solutions are used by health insurances, governments, hospital payers, and pharmaceutical companies around the globe to dramatically reduce the administrative burden of implementing and managing complex drug pricing agreements and to optimize rebates and get better value from those agreements. Lyfegen maintains the world’s largest digital repository of innovative drug pricing models and public agreements and offers access to a robust drug pricing simulator designed to dynamically simulate complex drug pricing scenarios to understand full financial impact. Headquartered in Basel, Switzerland, the company was founded in 2018 and has a market presence in Europe, North America, and the Middle East.

Cavos Biotech is an emerging genomic and data science company focusing on the development of novel drugs based on naturally occurring resistance mechanisms for various diseases. We are developing a multi-level genomic algorithm to uncover the genetic base of extraordinary cancer resistance found in specific, and across various animals. We harness the genomic and data revolution and use high resolution identification methods to uncover existing anti-cancer mechanisms, and novel drug targets, and to revolutionize the way by which drug targets are discovered and identified.

MetaSight Diagnostics, a health technology company, is on a mission to create affordable and precise liquid biopsy diagnostics for early detection of a variety of chronic and acute diseases, utilizing proprietary, cost-effective mass spectrometry technologies (metabolomics, lipidomics and proteomics). The company has created the world’s largest and most comprehensive serum metabolomics dataset linked with Electronic Health Records and is pursuing additional omics. This unprecedented platform is used by MetaSight’s team of experts in analytical chemistry, AI, and medicine to develop and commercialize diagnostic products to improve human health.

Lin Health partners with payers and providers to help people reclaim their lives from chronic pain through human-led, tech-enabled, highly personalized care. Our award-winning, comprehensive approach applies the latest neuroscience to treat conditions as diverse as migraines, IBS, and back and joint pain. We partner with health systems, clinics, and payers as an integrated extension of the care team to offer patients an affordable, immediately accessible, and non-pharmacological solution for highly prevalent neuroplastic pain. Our clinically validated intervention targets the nervous system by combining the most effective pain signaling techniques, incorporating multidisciplinary clinical guidance, high-frequency coaching, evidence-based digital resources, and proprietary technology to improve patient outcomes, patient and provider satisfaction, and clinic success. Our proprietary AI-based Care Platform provides rapid scalability and has served thousands of patients in the past 12-months. Lin Health was founded by industry veterans and is funded by leading investors.

Nectin Therapeutics is a biotech company focused on unlocking the power of the immune system. We are developing a collection of next-generation immunotherapy agents. Despite the unprecedented efficacy of existing immunotherapy agents, many patients either fail to respond, or following encouraging initial response, develop resistance over time. At Nectin, we have discovered novel resistance mechanisms and developed novel agents targeting these mechanisms for improved therapy. At Nectin, we are dedicated to the development of novel therapeutic options for cancer patients. We are developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, we develop CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers.